Immunohistochemical investigation of CD34 antigen in male breast carcinoma

2007 ◽  
Vol 7 (3) ◽  
pp. 122-126 ◽  
Author(s):  
S. Milias ◽  
H. Kalekou ◽  
M. Bobos ◽  
G. Karayannopoulou ◽  
D. Gerasimidou ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Male Breast ◽  
Immunohistochemical Investigation ◽  
Male Breast Carcinoma ◽  
Cd34 Antigen

Male breast carcinoma in Israel

Cancer ◽  
2002 ◽  
Vol 94 (8) ◽  
pp. 2128-2133 ◽  
Author(s):  
Baruch Brenner ◽  
Georgeta Fried ◽  
Pavel Levitzki ◽  
Erica Rakowsky ◽  
Hedwig Lurie ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Male Breast ◽  
Male Breast Carcinoma

Expression of oncogene and anti-oncogene in male breast carcinoma

1995 ◽  
Vol 7 (1) ◽  
pp. 38-43
Author(s):  
Liangzhong Xu ◽  
Tingqiu Zhang ◽  
Xiaojuan Hu ◽  
Jie Zhang
Keyword(s):  
Breast Carcinoma ◽  
Male Breast ◽  
Male Breast Carcinoma

Sentinel lymph node biopsy in patients with male breast carcinoma

Cancer ◽  
2001 ◽  
Vol 91 (2) ◽  
pp. 319-323 ◽  
Author(s):  
Elisa Rush Port ◽  
Jane V. Fey ◽  
Hiram S. Cody ◽  
Patrick I. Borgen
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Sentinel Lymph Node Biopsy ◽  
Breast Carcinoma ◽  
Lymph Node Biopsy ◽  
Male Breast ◽  
Male Breast Carcinoma ◽  
Node Biopsy

Oncogenes and Male Breast Carcinoma: c-erbB-2 and p53 Coexpression Predicts a Poor Survival

2000 ◽  
Vol 18 (16) ◽  
pp. 2948-2956 ◽  
Author(s):  
Achille Pich ◽  
Elena Margaria ◽  
Luigi Chiusa
Keyword(s):  
Breast Carcinoma ◽  
Prognostic Value ◽  
Ductal Carcinoma ◽  
Univariate Analysis ◽  
Prognostic Significance ◽  
Male Breast ◽  
Male Breast Carcinoma ◽  
P53 Immunoreactivity ◽  
Mib 1

PURPOSE: To investigate the prognostic value of biomarkers in male breast carcinoma (MBC). PATIENTS AND METHODS: Fifty patients (mean age, 62.2 years) with invasive ductal carcinoma were retrospectively studied. All patients received surgery; 35 had adjuvant postoperative therapy. The median follow-up was 59 months (range, 1 to 230 months). c-myc, c-erbB-2, p53, and bcl-2 proteins were immunohistochemically detected on sections from formalin-fixed, paraffin-embedded tissues using 9E11, CB11, DO7, and bcl-2 124 monoclonal antibodies (mAbs). Estrogen, progesterone, and androgen receptors were detected using specific mAbs. Cell proliferation was assessed by MIB-1 mAb. RESULTS: In univariate analysis, c-myc, c-erbB-2, and p53 protein overexpression was significantly correlated with prognosis. The median survival was 107 months for c-myc–negative and 52 months for c-myc–positive patients (P = .01), 96 months for c-erbB-2–negative and 39 months for c-erbB-2–positive patients (P = .02), and 100 months for p53-negative and 33 months for p53-positive patients (P = .0008). Tumor histologic grade (P = .01), tumor size (P = .02), patient age at diagnosis (P = .03), and MIB-1 scores (P = .0004) also had prognostic value. In multivariate analysis, only c-erbB-2 and p53 immunoreactivity retained independent prognostic significance. All nine patients who did not express c-erbB-2 and p53 proteins were alive after 58 months, whereas none of the 14 patients expressing both proteins survived at 61 months follow-up (P = .0002). CONCLUSION: Overexpression of c-myc, c-erbB-2, and p53 proteins may be regarded as an additional prognostic factor in MBC. The combination of c-erbB-2 and p53 immunoreactivity can stratify patients into different risk groups.

Expression of cathepsin D and estrogen receptor in male breast carcinoma

1993 ◽  
Vol 24 (2) ◽  
pp. 148-151 ◽  
Author(s):  
Suzanne Rogers ◽  
Christopher A. Day ◽  
Stephen B. Fox
Keyword(s):  
Estrogen Receptor ◽  
Breast Carcinoma ◽  
Cathepsin D ◽  
Male Breast ◽  
Male Breast Carcinoma

scholarly journals Familial male breast carcinoma

Cancer ◽  
1990 ◽  
Vol 65 (10) ◽  
pp. 2342-2343 ◽  
Author(s):  
Joseph G. Demeter ◽  
Norton G. Waterman ◽  
Gerald D. Verdi
Keyword(s):  
Breast Carcinoma ◽  
Male Breast ◽  
Male Breast Carcinoma
Sign in / Sign up

Export Citation Format

Share Document